New Market Research Report: South Korea Pharmaceuticals & Healthcare Report Q2 2014

From: Fast Market Research, Inc.
Published: Wed Feb 12 2014


We highlight that, despite challenging conditions, South Korea does offer some form of certainty given that the government has yet to initiate fresh rounds of extensive medicine price cuts, providing short-term stability to the pharmaceutical market. Stringent price containment goes against the country's aim to develop its pharmaceutical sector, and therefore in order to foster the sector's growth, potential changes must be made to drug pricing regulation, representing an upside risk to our outlook.

Headline Expenditure Projections

* Pharmaceuticals: KRW16,106.7bn (US$14.45bn) in 2013 to KRW16,543.74bn (US$15.04bn) in 2014; +2.7% in local currency terms and +4.1% in US dollar terms.
* Healthcare: KRW101,672bn (US$91.19bn) in 2013 to KRW108,555bn (US$98.69bn) in 2014; +6.8% in local currency terms and +8.2% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/775200_south_korea_pharmaceuticals_healthcare_report_q2.aspx?afid=303

Risk/Reward Ratings

In Q2 2014, South Korea ranks fourth out of the 19 countries surveyed in the Asia Pacific region. South Korea's score for its Rewards variable is third to Japan, Taiwan and China, indicating the country's favourable longer-term standing in terms of its pharmaceutical market development. However, we note that risks - particularly in relation to pharmaceutical pricing and reimbursement - will remain present, especially as the population ages and requires more public sector resources.

Key Trends & Developments

* In January 2014, Allergan and Medytox closed the licence agreement that was previously announced on September 25 2013. Under the terms of the agreement, Allergan will pay Medytox an up-front cash payment of US$65mn within seven business days of closing. Medytox has granted Allergan exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialise certain neurotoxin product candidates currently in development, including a potential liquid injectable product.
* In December 2014, the Ministry of Health and Welfare announced that it will implement its market-based actual transaction price (M-ATP) system, effective from February 2014. Following the announcement, six pharmaceutical industry interest groups, including the Korean Pharmaceutical Manufacturers Association, the Korean Pharmaceutical Wholesalers Association, and the Korean Research-based Pharmaceutical Industry Association, released a joint statement objecting to the proposal, stating that it will negatively affect the growth of the pharmaceutical industry.
* In November 2014, Hanmi Pharmaceutical announced that the first fixed dose combination (FDC) drug composed of ARB (angiotensin receptor blocker) hypertension drug and the Statin hyperlipidaemia drug has received marketing approval from the Korean Food and Drug Administration (KFDA) in Korea. The FDC drug, dubbed Rovelito, was jointly developed with Sanofi-Aventis Korea.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Africa Pharmaceuticals & Healthcare Report Q1 2014
- Croatia Pharmaceuticals & Healthcare Report Q2 2014
- Australia Pharmaceuticals & Healthcare Report Q2 2014
- Nigeria Pharmaceuticals & Healthcare Report Q2 2014
- Mexico Pharmaceuticals & Healthcare Report Q2 2014
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »